MO vs XXII: Which Is the Better Buy in 2026?
Last updated August 2026
Short answer
MO is the larger of the two ($114.09B market cap): the incumbent the market prices for continued execution (11.65x forward earnings, beta 0.49). XXII is the smaller challenger ($1.38M), priced similarly on forward earnings (-0.26x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
MO vs XXII: the tie-breaker metrics
Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | MO | XXII | What it tells you |
|---|---|---|---|
| Market cap | $114.09B | $1.38M | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 11.65 | -0.26 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 0.49 | 0.67 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 61% of range | 0% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
Before you buy: how MO and XXII affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. MO and XXII share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined MO and XXII exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Altria (MO) do?
Altria Group is one of the largest tobacco companies in the United States, best known for the Marlboro cigarette brand sold through its Philip Morris USA subsidiary. Altria's core business is selling combustible cigarettes in the US market, where Marlboro holds a dominant share. Despite long-term declines in cigarette smoking rates, Altria has historically sustained revenue and profit by raising prices faster than volumes fall, a pricing power rooted in brand loyalty and an addictive product. The company also owns smokeless and oral tobacco brands (Copenhagen, Skoal, and the on! nicotine pouch line), the NJOY e-vapor brand, and stakes in other businesses. Altria is structured as a high-cash-return company: it pays one of the largest dividend yields among large-cap US stocks and returns substantial cash to shareholders through dividends and buybacks. The central long-term challenge is the secular decline of cigarette smoking and the company's mixed track record in transitioning to reduced-risk products. Founded in its modern form after the Philip Morris International spin-off in 2008 and headquartered in Richmond, Virginia, Altria is a defensive, high-yield consumer-staples stock.
What does 22nd Century Group (XXII) do?
22nd Century Group Inc. is a tobacco and plant-biotechnology company best known for VLN, its reduced-nicotine-content combustible cigarette, which is the only such product the FDA has authorized to be marketed with reduced-nicotine claims. The company has been commercializing VLN through retail trials in a growing number of US states (including a 2026 expansion into California under the Pinnacle VLN brand) and advancing additional PMTA submissions and licensing plans, including a 100mm-length product aimed at a larger share of the US cigarette market. It also runs contract-manufacturing of conventional tobacco products and has interests in hemp/cannabis and other plant-science lines, though tobacco is the core. The bull thesis rests heavily on regulation: a long-discussed FDA proposal to mandate very low nicotine levels in cigarettes would, if enacted, position VLN's technology at the center of the market.
MO vs XXII: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- MO drivers: Pricing power and Marlboro dominance; High dividend and cash returns.
- XXII drivers: FDA reduced-nicotine rule as the core catalyst; VLN commercialization and state-by-state expansion.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The central risk is the secular decline in US cigarette smoking, which steadily shrinks Altria's core volumes; at some point pricing may not fully offset falling volumes. For XXII, the risks here are severe and central to the story.
MO or XXII: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick MO if you believe its drivers more; XXII if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the MO and XXII guides.
MO vs XXII: the full fundamentals
MO. Altria trades at a low earnings multiple and a very high dividend yield, reflecting the market's view of declining cigarette volumes and heavy regulatory risk against durable pricing power and cash generation. The low multiple is the trade-off for an income stream most investors expect to grow slowly at best. ESG exclusions and secular concerns keep the valuation compressed.
XXII. All figures are approximate, tied to the asOf date, and must be verified against the latest SEC filings before acting; reverse splits and financings can change the share count and per-share figures dramatically between filings. Because the company is loss-making, price-to-earnings and similar multiples are not meaningful. What matters is cash runway, the pace of dilution, listing compliance, and whether the FDA reduced-nicotine mandate advances. Treat any headline number here as a starting point for your own research, not a precise metric, and recognize this is among the higher-risk names an investor can hold.
Headline figures (approximate, early 2026): MO shows revenue (ttm) ~$20 billion (net of excise taxes; ~$24 billion gross), operating margin ~55% (high, reflecting cigarette pricing power), net income (ttm) ~$8-11 billion (varies with one-time items), eps (adjusted) ~$5.20; XXII shows revenue trend Small (roughly the mid-teens of millions of dollars in 2025); quarterly revenue has been modest, in the low single-digit millions, figures approximate and to be verified live, profitability Unprofitable, with continued gross and operating losses; going-concern pressure has been a recurring theme in the company's history, balance sheet Fragile; the company has relied on repeated dilutive equity and warrant financings to fund operations, so cash runway is a live question, verify the latest filing, share structure Repeatedly reverse-split (including 1-for-135 in Dec 2024 plus further splits in 2025 and 2026) to keep the Nasdaq minimum bid price; share count has been reset several times.
The bottom line: MO vs XXII
MO and XXII are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined MO and XXII exposure against your real portfolio. It is not an investment adviser.
Wondering how MO or XXII fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in Altria with AI
Connect the broker you already use and ask Walnut's AI how MO fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between MO and XXII?
+
Altria Group is one of the largest tobacco companies in the United States, best known for the Marlboro cigarette brand sold through its Philip Morris USA subsidiary. 22nd Century Group Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is MO or XXII the better stock?
+
Neither is universally better. MO is the larger incumbent; XXII is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, MO or XXII?
+
On forward P/E (as of August 2026), MO trades at 11.65x and XXII at -0.26x, so XXII is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both MO and XXII?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of MO vs XXII?
+
MO: The central risk is the secular decline in US cigarette smoking, which steadily shrinks Altria's core volumes; at some point pricing may not fully offset falling volumes. Regulatory threats are severe and ongoing: potential FDA menthol bans, proposals to cap nicotine levels, flavored-product restrictions, and excise-tax increases could all impair the business. Altria's transition to reduced-risk products has been uneven, including a large write-down on its prior Juul investment. Litigation and reputational risk are persistent. The high payout limits reinvestment flexibility, and illicit and competing nicotine products (including disposable vapes) erode share. ESG exclusions limit the investor base. The stock can stagnate when volume declines accelerate faster than pricing can offset. XXII: The risks here are severe and central to the story. 22nd Century has a history of operating losses and going-concern warnings, and it has funded itself through repeated dilutive equity and warrant issuance, so existing shareholders have been diluted heavily and could be again. Multiple large reverse stock splits (including 1-for-135 in December 2024 and further splits in 2025 and 2026) have been used to maintain the Nasdaq minimum bid price; reverse splits do not create value and often precede further declines. The core VLN thesis depends on an FDA reduced-nicotine mandate that has been proposed and delayed before and may never take effect, making a large part of the upside binary and outside the company's control. Tobacco regulation, litigation exposure, small revenue, thin trading, and the ever-present possibility of delisting all compound the risk. This is a distressed micro-cap that can lose value quickly and should be sized accordingly.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell MO or XXII; figures are approximate and dated (as of August 2026). Verify current data before investing.